Researchers Reveal Connection Between Female Estrogen Cycle and Addictive Potential of Cocaine
Hormonal fluctuations women undergo make them particularly sensitive, compared to men, to the addictive properties of cocaine, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published January 10 in the journal Nature Communications.
The Mount Sinai research team discovered that estrogen intensifies the brain’s dopamine reward pathway and demonstrated that cocaine has its most potent effects during the estrous/menstrual cycle, when release of estrogen is at its highest. Their research suggests that a possible addiction intervention could be to adjust this hormonal cycle through use of birth control pills or a similar strategy.
“Our study will change the way we think about addiction research to emphasize the need to further understand female subjects, as most research on addiction has been conducted in male subjects,” says Erin Calipari, PhD, co-first author on the paper and a postdoctoral fellow at the Icahn School of Medicine. “Further study of the estrogen-reward pathway is important, as it is quite possible that estrogen may have similar effects on other forms of substance abuse.”
Dr. Calipari is a member of the Laboratory of Molecular Psychiatry, led by the study’s senior investigator, Eric Nestler, MD, PhD, Nash Family Professor of Neuroscience and Director of The Friedman Brain Institute at the Icahn School of Medicine.
The Mount Sinai research team sought to understand why women, once they try cocaine, are much more likely than men to become addicted. While the overall rate of addiction is higher in males, previous research has shown that when females have the opportunity to try cocaine and other drugs, they are more likely than men to continue use and they transition to full addiction significantly faster than their male counterparts. Addiction investigators have also uncovered that women are more likely to use cocaine at an earlier age, take the drug in larger quantities, and have greater difficulty remaining abstinent compared to men. Additionally, women report that when estrogen levels are rising during their menstrual cycles, they experience a greater “high” from cocaine administration.
To understand why this occurs, researchers used mice — animals that show the same sex differences in drug use as humans — and fixed tiny fiber-optic probes to specific areas of the brain, including those involved in the dopamine reward pathway. Female mice at various points in their estrus cycle, as well as male mice, were studied.
The research team found that estrogen affects the quantity of dopamine released by neurons in response to cocaine, as well as how long the dopamine stays in the synapse between brain cells. Both actions increase the pleasurable effects of cocaine, and each was significantly bolstered as estrogen levels increased in the female mice. Both male and female mice linked pleasure/reward to where it occurred in their cages, spending more time on the side of their cage that was previously paired with cocaine. Female mice did so to a greater extent, indicating enhanced reward to cocaine use.
“The mice quickly learned that a particular environment is linked to drugs, and we demonstrated that when these mice, especially females at the height of their estrous cycle, were put into that environment, it stimulated a dopamine reward signal even without cocaine use,” Dr. Calipari says. “It is the same kind of strong, learned response that we know happens in humans.”
Researchers surmise that the evolutionary mechanism underlying the link between estrogen and the reward pathway is pleasure from seeking a mate and having sex, actions which promote the survival of the species. Another evolutionary hypothesis is that heightened estrogen could promote food seeking, via effects on dopamine signaling, to ensure females are healthy enough to carry offspring. However, the estrogen in the brains of women that likely primes their response to survival-related rewards can also make them more vulnerable to addiction.
“Our findings underscore the unique insight into normal brain function and disease pathology that results from studying both sexes,” emphasizes Dr. Nestler, the principal author of the study. “This approach is essential to enable the field to develop optimized treatments for drug addition and other conditions for women as well as men.”
This work was performed collaboratively between several laboratories at Mount Sinai and at Stanford University. It was supported by the National Institute on Drug Abuse (E.J.N., R01 DA14133, P01 DA008227; E.S.C. K99 DA042111); The Brain and Behavior Research Foundation (NARSAD, M.H.H. and
E.S.C.); National Institute of Mental Health (E.J.N., R01 MH051399, P50 MH096890, M.H.H. R21 MH112081;) and National Institute of Alcoholism and Alcohol Abuse (M.H.H. R01 AA022445; B.J. F31 AA022862).
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in 4 out of 10 pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.